EULAR 2019 Conference Review - reviewed by Associate Professor Paul Bird

In this review:

Serious infections in offspring exposed to biologics
Efficacy of filgotinib vs placebo in active PsA
Bimekizumab in patients with active PsA
Efficacy and safety of ixekizumab vs adalimumab in PsA
Ixekizumab for PsA, efficacy in different patient subsets
Ixekizumab for treatment of radiographic axial spondyloarthritis
Long-term safety of baricitinib for RA
Long-term safety and efficacy of upadacitinib in RA
Upadacitinib vs adalimumab in RA
In vitro implications for differentiation among JAK inhibitors

Please login below to download this issue (PDF)